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Abstract
The YAP and TAZ transcriptional coactivators promote oncogenic transformation. Elevated
YAP/TAZ activity has been documented in human tumors. YAP and TAZ are negatively reg-
ulated by the Hippo tumor suppressor pathway. The activity and stability of several Hippo
pathway components, including YAP/TAZ, is regulated by ubiquitin mediated protein turn-
over and several ubiquitin ligase complexes have been implicated in human cancer. How-
ever, little is known about the deubiquitylating enzymes that counteract these ubiquitin
ligases in regulation of the Hippo pathway. Here we identify the DUB3 family deubiquitylat-
ing enzymes as regulators of Hippo pathway activity. We provide evidence that DUB3 pro-
teins regulate YAP/TAZ activity by controlling the stability of the E3 ligase ITCH, the LATS
kinases and the AMOT family proteins. As a novel Hippo pathway regulator, DUB3 has the
potential to act a tumor suppressor by limiting YAP activity.
Introduction
Transcriptional co-activators Yes-Associated Protein 1 (YAP1) and transcriptional coactivator
with PDZ-binding motif (TAZ) mediate the activity of the Hippo signaling pathway in control
of cell proliferation and in tumor progression [1]. YAP and TAZ bind to a number of different
transcription factors to regulate genes required for cell proliferation and survival [2]. Increases
in YAP/TAZ expression by epigenetic regulation and gene amplification have been observed
in human cancers, as have mutations in the upstream elements of the Hippo pathway that alle-
viate Hippo mediated repression of YAP/TAZ activity [3–5]. More recently, increased YAP
activity has been shown to be sufficient to replace the requirement for oncogenic K-Ras in
models of pancreatic and colon cancer [6,7], and in the transformation of primary human cells
to create cancer cells [8,9]. By limiting YAP/TAZ activity, the Hippo pathway serves as a bar-
rier to cellular transformation and tumor formation.
A number of different mechanisms have been reported by which ubiquitin-mediated pro-
tein turnover regulates YAP/TAZ activity. The best studied of these involves the targeting of
YAP and TAZ for destruction by the βTrCP/SCF ubiquitin ligase system, as a consequence of
LATS1/2 mediated phosphorylation of YAP and TAZ [10,11]. Destruction of YAP and TAZ
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contributes to the tumor suppressive effects of the Hippo signaling pathway. Conversely, the
transforming potential of oncogenic Ras is mediated in part through promoting YAP/TAZ
stability. Ras acts by downregulating the expression of the substrate recognition factors that
recruit YAP to an Elongin B/C-Cullin5 ubiquitin ligase complex [8]. Ubiquitin-mediated pro-
tein turnover is involved in regulating the activity of a number of other Hippo pathway com-
ponents. Mechanisms for regulation of LATS kinase activity and turnover have been reported.
The E3 ubiquitin ligases ITCH and NEDD4 have been shown to promote turnover of LATS
kinases, and ITCH upregulation can promote tumorigenesis through increased YAP/TAZ
activity [12] [13,14]. The RING ligase PRAJA2 promotes turnover of MOB1, a regulator of
LATS kinases, and has been implicated in glioblastoma [15]. Other YAP/TAZ regulators are
also controlled by ubiquitylation. Angiomotin (AMOT) and the related AMOT-like proteins
interact with both LATS kinases and with YAP. AMOT proteins inhibit YAP/TAZ activity
through direct physical association and by promoting LATS-mediated phosphorylation of
YAP [16,17]. AMOT turnover is regulated by ITCH and other Nedd4 ubiquitin ligase family
members [18]. Thus, ubiquitin-based protein turnover acts at multiple levels in the core Hippo
pathway as well as in ancillary pathways to control YAP/TAZ stability and activity.
The activity of ubiquitin ligases in promoting protein turnover can be counteracted by deu-
biquitylating enzymes that remove ubiquitin moieties from proteins. Evidence is emerging that
deubiquitylating enzymes may act as oncogenes and tumor suppressors [19–22]. Using a cell-
based RNAi screen for YAP/TAZ activity, we recently identified the deubiquitylating enzyme
USP9x as a negative regulator of YAP/TAZ activity, acting through regulation of AMOT turn-
over [23]. These findings provide a molecular framework for the observation that low USP9x
expression correlated with poor survival of renal clear cell carcinoma [23] and that USP9x is
downregulated in pancreatic ductal adenocarcinoma [22].
In this report, we present evidence implicating the family of DUB3 deubiquitylating enzymes
in control of Yap/TAZ activity. DUB3 proteins act by regulating the stability of the E3 ubiquitin
ligase ITCH, the Hippo pathway core kinases LATS1 and LATS2, as well as the family of AMOT
proteins, which play a scaffolding role in DUB3-mediated regulation of YAP.
Materials and Methods
Antibodies
Antibodies to NEDD4 (Cat #2740), ITCH (#12117), SMURF1 (#2174), phosphor-YAP (S127,
#4911), YAP (#4912), YAP/TAZ (#8418), phospho-LATS1 (T1079,#8654), LATS1 (#9153),
LATS2 (#13646), specific K48 and K63 ubiquitin and Myc Tag (#2278) were from Cell Signal-
ing Technology (Danvers, MA, USA). HA (#sc-7392) and YAP (sc#101199) antibodies were
from Santa Cruz Biotechnology (Dallas, TX, USA). Anti-AMOT was from ABNOVA (Taipei,
Taiwan). Anti-Flag antibody and anti-Actin, HA-, Myc- and Flag-conjugated beads were from
Sigma-Aldrich, St Louis, MO, USA). DUB3 antibody (Cat#PA-5-44961) was obtained from
Invitrogen (Taastrup, Denmark).
Plasmids and siRNAs
The DUB shRNA library was described in [23]. 8xGTIIC-luciferase was a gift from Stefano Pic-
colo (Addgene plasmid # 34615). The pRL-CMV (Renilla, #E2261) was purchased from Pro-
mega (Madison, WI, USA). pBabe HA-LATS2 and HA-p130 AMOT expressing plasmids were
kind gifts from SW Chan (IMCB). Flag-DUB3 was cloned from cDNA of 293T cells by PCR
into a pBabe (puro) expression vector using the following primers: ATACGGATCCACCATGGA
CTACAAGGATGACGATGACAAGGACTACAAGGATGACGATGACAAGGAGGACGACTCACTCTA
CTT and ATCAGAATTCTCACTGGCACACAAGCAGAG. The PCR product was sequenced and
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Abbreviations: DUB, deubiquitylating enzyme;
YAP, Yes-Associated Protein; TAZ, transcriptional
coactivator with PDZ-binding motif; AMOT,
angiomotin; LATS, large tumor suppressor;
NEED4, neural precursor cell expressed
developmentally down-regulated protein 4.
encodes the USP17L17 isoform of DUB3. The C89S mutant was made by PCR as previously
described [24], and confirmed by sequencing. LATS2 shRNA was described in [25]. The pBabe
vector expressing Myc-ITCH was subcloned from the PCINeo-myc-ITCH plasmid, which was
a gift from Allan Weissman (Addgene plasmid # 11427). Single and smart pool siRNAs against
LATS2, AMOT, AMOT L1, AMOT L2, ITCH, NEDD4 and DUB3 were purchased from GE
Dharmacon (Brøndby, Denmark). Details of the siRNA sequences used to deplete DUB3 family
members are provided in S1 Table.
Luciferase assays
Luciferase assay to measure YAP/TAZ activity were performed as described [23] using a dual
luciferase kit (E1960, Promega).
Quantitative real-time RT-PCR
RNA was extracted in Trizol (Invitrogen) and pretreated with DNAse (RQ1, Promega) before
being used for cDNA synthesis. cDNA was made using iScript (BioRad) with random hexamer
primers. At least two pairs of qPCR primers were tested for specificity and sensitivity for each
mRNA. Real-time PCR used SyberGreen I Mix on a QuantStudio 6 Flex machine (ABI,
Thermo Fisher Scientific, Waltham, MA, USA). As DUB3 is an intron-less gene, a parallel
analysis of non-iScript and iScript treated cDNA was performed to exclude the possibility of
amplification from genomic DNA-contaminated samples. Primer sequences are in S1 Table.
Cell culture, transfection, immunoprecipitation and blotting
BJ foreskin fibroblasts and HEK293T cells were obtained from ATCC and cultured in DMEM
(Sigma) with 10% fetal calf serum (HyClone) and 1% penicillin-streptomycin. HEK293T cells
were transfected with using the Calcium phosphate method. BJ fibroblast cells were transfected
using Fugene HD (Promega) according the manufacturer’s instructions. For immunoblotting,
transfected cells were washed with cold TBS after 48h and lysed in modified RIPA buffer con-
taining 25mM Tris/HCl, pH 7.5, 150mM NaCl, 0.5% Nonidet NP40, 0.1% Na-deoxycholate,
1mM EDTA, 0.5% Triton X-100, 5mM NaF, 5mM β-glycerophosphate, 1mM Na3VO4 and
protease inhibitor cocktail. After incubation with antibody, blots were developed with Western
Lightning Plus-ECL reagent (PerkinElmer). For co-immunoprecipitation assays, cells were
pretreated with 5μM MG132 overnight before being harvested for immunoprecipitation.
Transfected cells were washed once with cold TBS (20mM Tris-HCl pH 7.5, 150mM NaCl)
and lysed with PLC buffer [26] containing 50 mM HEPES pH 7.5, 150 mM NaCl, 5% Glycerol,
0.5% Triton X-100, 1.5 mM MgCl2, 1 mM EGTA supplemented with 20 μg/ml RNAase A, 1
mM DTT, 1 mM Na3VO4 and protease inhibitor cocktail. Cell lysates were pre-cleared with
proteins A/G beads (Santa Cruz, sc#2003) and immunoprecipitated for 2 hours at 4˚C with
anti-HA, or–Myc or -Flag agarose beads. Beads were washed 4x with lysis buffer and eluted as
recommended by the manufacturer. For ubiquitin assays, a minimal amount of ITCH expres-
sion plasmid (3μg) was used to co-transfect with 2μg of ubiquitin expression plasmids in
10-cm disc of HEK293T cells and the PLC lysis buffer was freshly supplemented with 10mM
of N-ethylmaleimide (NEM, Sigma).
Statistical analyses
Differences among conditions and treatments for luciferase assays, quantitative PCR and cell
growth assays were determined using the Student’s t-test (2-tailed, unequal variance). For
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assessing differences in subcellular localization of YAP localization, the Chi-square test was
used.
Results and Discussion
DUB3 regulates YAP activity
The DUB3 family of deubiquitylating enzymes was identified in a shRNA-based screen for reg-
ulators of YAP/TAZ activity [23]. The DUB3 family includes 25 USP17-like proteins. These
proteins are encoded, in varying numbers, in tandem repetitive sequences in human genomes
[27,28]. Sequence divergence among the members of this family is low, however, no single
siRNA or shRNA sequence targets all family members, nor are there reagents that allow selec-
tive targeting of only one family member (S1 Fig). Quantitative PCR and immunoblot analysis
showed that the shRNAs and siRNA pools used in this study were effective in depleting the
family of DUB3 transcripts and proteins (S2 Fig).
Depletion of DUB3 transcripts by three independent shRNAs significantly increased YAP/
TAZ reporter activity (Fig 1A). Depletion of LATS2 was used as a positive control for increased
YAP/TAZ activity in this assay. This was verified using two additional pools of siRNAs to
deplete DUB3 (Fig 1B; controls are in S2 Fig). Reciprocally, overexpression of DUB3 led to a
significant reduction of YAP reporter activity (Fig 1C). Expression of a catalytically inactive
mutant form of DUB3 (C89S, [29]) had no effect on YAP luciferase reporter activity (Fig 1C),
indicating that the enzymatic activity of DUB3 is required for its effects on YAP activity.
Immunoblotting of lysates from cells overexpressing DUB3 showed a marked decrease in
the level of YAP protein, consistent with the decrease in the luciferase reporter assay (Fig 1D;
YAP mRNA levels were not affected, S3 Fig). The catalytically inactive C89S form of DUB3
had no effect on YAP levels (Fig 1D). Reciprocally, depletion of DUB3 proteins with two inde-
pendent siRNA pools led to an increase in YAP protein levels (Fig 1E) and to a significant
increase in expression of YAP transcriptional targets Cyr61 and ANKRD1 (Fig 1F). Compara-
ble results were obtained by depleting DUB3 in BJ cells (S4 Fig). Nuclear localization of YAP
increased in BJ cells depleted of DUB3 compared to control cells, consistent with the observed
increase in YAP reporter activity and target gene expression (S4 Fig and S5 Fig). These data
indicate that DUB3 regulates the abundance of YAP protein, its subcellular localization and
the expression of its targets.
DUB3 inhibits cell growth through regulating Hippo pathway activity
YAP acts through TEAD proteins to regulate a number of targets that promote cell growth and
proliferation [30]. Our results showed that DUB3 inhibits YAP/TAZ activity; we asked
whether this inhibition would affect Hippo-mediated cell growth and proliferation. To investi-
gate this, we utilized human primary fibroblast BJ cells (BJp53kd/p16kd/HRas), in which cell
growth is affected by modulating Hippo activity [9]. Co-expression of DUB3 significantly
reduced growth of these cells, compared to cells expressing the catalytically inactive C89S
mutant form of DUB3 or the control vector (Fig 1G). DUB3 expression had a more limited
effect on the growth of BJ cells expressing a mutant form of YAP (S127A/S397A) that is not
regulated by LATS kinases (BJp53kd/p16kd/HRas/YAPS127A/S397A; Fig 1G). The residual effect of
DUB3 may be due to the endogenous wild-type YAP that is also expressed in these cells.
DUB3 acts via the E3 ubiquitin ligase ITCH
As a deubiquitylating enzyme, overexpression of DUB3 is expected to remove ubiquitin from
its direct targets, thereby increasing their stability. However, we observed that overexpression
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Fig 1. DUB3 regulates Hippo activity by mediating YAP turnover. (A) Luciferase reporter assays showing
the effects of DUB3 shRNAs on YAP/TAZ activity. HEK293T cells were transfected to express the 8XGTIIC_luc
YAP/TAZ reporter, which contains 8 TEAD binding sites to control the expression of firefly luciferase and a
vector expressing CMV-Renilla luciferase to normalize for transfection efficiency, together with independent
shRNA vectors to deplete DUB3 or with a control shRNA. shRNA to deplete LATS2 was used as a positive
control. Data represent the average of three independent transfection experiments ± SD. P values were
determined using Student’s T-test (2-tailed, unequal variance). (B) Luciferase reporter assays showing the
effects of DUB3 siRNAs on YAP/TAZ activity. HEK293T cells were transfected to express the luciferase re-
porters together with independent siRNAs to deplete DUB3 or with a control scrambled siRNA. Data represent
the average of three independent transfection experiments ± SD. P values were determined using Student’s
T-test (2-tailed, unequal variance). (C) Luciferase reporter assays showing the effect of DUB3 on YAP/TAZ
activity. HEK293T cells were transfected to express the luciferase reporters together with a vector expressing
Flag-DUB3, the C89S mutant form of DUB3 or relevant controls vectors. shRNA to deplete LATS2 was used
as a positive control. Data represent the average of three independent replicates ±SD. P values were deter-
mined using Student’s T-test (2-tailed, unequal variance). (D) Immunoblots showing the effect of DUB3
expression on YAP protein. HEK293T cells were transfected with a vector expressing Flag-DUB3, the C89S
mutant form of DUB3 or a control vector. Blots were probed with anti-YAP antibody and anti-Flag. Anti-Actin
was used to control for loading. (E) Immunoblots showing the effect of DUB3 depletion on the YAP expression
level. HEK293T cells were transfected with independent DUB3 siRNAs or a scrambled siRNA control. Blots
were probed with anti-YAP antibody and anti-Flag. Anti-Actin was used to control for loading. (F) Effect of
DUB3 siRNAs on the expression of YAP transcriptional targets. HEK293T cells were transfected with DUB3
or control siRNAs. mRNA expression of DUB3, Cyr61, ANKRD1 was measured by RT-PCR. GAPDH mRNA
was used for normalization and TBP was used as an additional control gene. Data represent the average of 3
independent experiments ±SD. * indicates p <0.01, compared to the relevant controls (Student’s T-test;
2-tailed, unequal variance). (G) Effect of DUB3 on cell growth. Human primary fibroblast BJ cells were
engineered to express hTert, H-RasG12V and to deplete p53 and p16, or with the addition or YAPS127A/S397A.
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of DUB3 led to a decrease in YAP protein levels. Conversely, depletion of DUB3 should
increase ubiquitylation, leading to a decrease in target protein levels. Instead, DUB3 depletion
increased YAP protein levels. DUB3 is therefore unlikely to act directly on YAP, so we tested
other regulators of YAP/TAZ activity to identify potential direct targets of DUB3.
Deubiquitylating enzymes have been reported to associate with ubiquitin E3 ligases and to
regulate their stability and activity [31]. We asked whether DUB3 overexpression affected the
expression of the E3 ligases known to regulate the Hippo pathway. ITCH and NEDD4 have
been implicated in turnover of LATS kinases and AMOT [12] [13,14,18]. Overexpression of
DUB3 led to a marked increase in ITCH protein, but had little or no effect on the amount of
NEDD4 or SMURF1 (Fig 2A). Expression of the catalytically inactive C98S form of DUB3 had
no significant effect on ITCH levels. Quantitative PCR showed no change in the levels of the
ITCH, NEDD4 or SMURF1 transcripts (S6 Fig). Reciprocally, siRNA-mediated depletion of
DUB3 proteins led to a decrease in ITCH protein levels (Fig 2B).
To investigate the possibility that DUB3 might act directly on ITCH, we tested for physical
interaction. Flag-tagged DUB3 was coexpressed with Myc-tagged ITCH. Lysates were immu-
noprecipitated with anti-Myc and probed with anti-Flag to detect DUB3. DUB3 was recovered
by co-precipitation with ITCH (Fig 2C). Likewise, ITCH was recovered by co-precipitation
with Flag-DUB3 (Fig 2C). Endogenous ITCH was pulled down by co-immunoprecipitation
with DUB3, but was not recovered in the control IgG immunoprecipitates (S7 Fig). These data
suggest that DUB3 physically interacts with ITCH.
Next, we asked whether DUB3 affects ubiquitylation of ITCH. Acting as an E3 ubiquitin
ligase, ITCH can auto-ubiquitylate in an intermolecular manner [32] [33]. The USP9x deubi-
quitylating enzyme has been shown to promote ITCH stability by counteracting auto-ubiqui-
tylation [32]. To monitor ITCH ubiquitylation, cells were transfected to express Myc-tagged
ITCH along with HA-tagged Ubiquitin and with Flag-tagged DUB3 or with a control vector.
Cells were incubated in the presence of the proteasome inhibitor MG132 to limit degradation
of ubiquitylated proteins. Myc-tagged ITCH was then recovered by immunoprecipitation and
the blots were probed with anti-HA to detect HA-tagged ubiquitin and with anti-Flag to detect
Flag-tagged DUB3. Expression of DUB3 strongly reduced the amount of poly-ubiquitylated
ITCH (Fig 2D). Expression of the inactive C89S mutant form of DUB3 had little or no effect
on ITCH ubiquitylation (Fig 2D). Reciprocally, depletion of DUB3 proteins led to an increase
in ITCH ubiquitylation (S8 Fig). These results suggest that DUB3 modulates ubiquitylation of
ITCH and thereby regulates its stability by protecting it from degradation.
DUB3 stabilizes LATS and AMOT proteins
ITCH-mediated ubiquitylation has been shown to promote the turnover of several Hippo
components, such as LATS kinases and AMOT proteins [12,18,34]. Our results suggest that
DUB3 promotes ITCH stability; we therefore asked if DUB3 would affect the stability of these
Hippo proteins as well. Interestingly, DUB3 expression increased the levels of AMOT,
AMOTL1, LATS1 and LATS2 and a decrease in YAP level. (Fig 3A; transcript levels were unaf-
fected, S3 Fig). Depletion of DUB3 led to a marked decrease in LATS1, LATS2 and AMOT lev-
els (Fig 3B). Decreased LATS levels are consistent with an increase in YAP levels (Fig 3B) and
with the observed effect on YAP reporter activity (Fig 1B).
BJp53kd/p16kd/HRas and BJp53kd/p16kd/HRas/YAPS127A/S397A cells were virally transduced and selected to stably
express DUB3, its inactive C89S mutant form or with an empty vector as a control. Cells were counted at
24-hour intervals for a period of 72h. The assay was performed in triplicate. Data represent the average ± SD.
* indicate p <0.05, compared to the relevant controls (Student’s T-test; 2-tailed, unequal variance).
doi:10.1371/journal.pone.0169587.g001
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These findings present an apparent conundrum: DUB3 interacts with ITCH and affects
ITCH ubiquitylation and stability, and higher ITCH expression should increase turnover of
LATS and AMOT. However, despite the increase in ITCH protein, LATS and AMOT were sta-
bilized as a consequence of DUB3 expression. Reciprocally, they were destabilized as a conse-
quence of DUB3 depletion. We therefore considered the possibility that DUB3 might directly
regulate the turnover of AMOT and LATS proteins.
We examined the effect of DUB3 depletion on AMOT ubiquitylation. In control cells,
DUB3 was recovered by co-precipitation with AMOT, providing evidence for physical interac-
tion (S9 Fig). Depletion of DUB3 led to a marked increase of AMOT ubiquitylation (S9 Fig).
Reciprocally, overexpression of DUB3 reduced the ubiquitylation of AMOT, while the inactive
C89S DUB3 mutant had no effect (S9 Fig). Likewise, we examined the interaction between
DUB3 and LATS2. LATS2 was recovered by co-immunoprecipitation of DUB3 (S10 Fig).
LATS2 ubiquitylation was markedly suppressed by overexpression of DUB3, but not by the
catalytically inactive C89S form of DUB3 (S10 Fig). These data provide evidence that DUB3
interacts with AMOT and LATS2 proteins and regulates their turnover.
Fig 2. DUB3 interacts with ITCH and mediates its stability. (A) Immunoblots showing the effect of DUB3
expression on ITCH. HEK293T cells were transfected with a vector expressing Flag-DUB3, its C89S DUB3
or a control vector. Blots were probed with anti-Flag, anti-ITCH, anti-NEDD4 and anti-SMURF1 antibodies.
Anti-Actin was used to control for loading. (B) Immunoblots showing the effect of DUB3 siRNAs on ITCH.
HEK293T cells were transfected with independent siRNAs against DUB3 or a scrambled siRNA. Blots were
probed with antibodies against ITCH or Actin for loading control. (C) Immunoprecipitation assays showing
interaction between DUB3 and ITCH. HEK293T cells were transfected to express Flag-tagged DUB3 and Myc-
tagged ITCH as indicated. Transfected cells were treated with MG132 5μM overnight before being harvested for
immunoprecipitation with anti-Flag or anti-Myc-conjugated beads. Blots were probed with anti- Flag to detect
DUB3 or anti-Myc to detect ITCH. (D) Ubiquitylation assay showing the effect of DUB3 on ITCH ubiquitylation.
HEK293T cells were co-transfected with a vector expressing Myc-ITCH and a vector expressing Flag-tagged
DUB3, Flag-tagged DUB3 C89S or a control vector. Transfected cells were treated with MG132 5μM overnight
before being harvested for immunoprecipitation with anti-Myc-or isotype IgG-conjugated beads in PLC buffer
freshly supplemented with 10mM of NEM. Immunoblots were probed with antibodies against HA, Flag and Myc.
doi:10.1371/journal.pone.0169587.g002
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Fig 3. LATS and AMOT proteins are required for DUB3-mediated regulation of Hippo signaling. (A)
Immunoblots showing the effect of DUB3 expression on LATS kinases, AMOT and YAP. HEK293T cells were
transfected with a vector expressing Flag-DUB3 or a control vector together with a mixture of siRNAs
targeting AMOT, AMOTL1 and AMOTL2 or a scrambled siRNA control. Blots were probed with antibodies
against Flag, AMOT, AMOTL1, LATS1, LATS2 and YAP. Anti-Actin was used to control for loading. Samples
were run on the same SDS-acrylamide gels with intervening lanes removed. (B) Immunoblots showing the
effect of DUB3 depletion on LATS kinases, AMOT and YAP. HEK293T cells were transfected with a vector
expressing Flag-DUB3 or a control vector together with a mixture of siRNAs targeting AMOT, AMOTL1 and
AMOTL2 or a scrambled siRNA control. Blots were probed with antibodies against DUB3, AMOT, LATS1,
LATS2 and YAP. Anti-Actin was used to control for loading. Samples were run on the same gels with
intervening lanes removed. (C) Immunoblots showing the effect of DUB3 depletion on ITCH, LATS kinases
and AMOT. HEK293T cells were transfected with a control or DUB3 siRNA in the presence of LATS1 and
LATS2 siRNAs or a scrambled siRNA control. Blots were probed with antibodies against DUB3, ITCH, AMOT,
LATS1, LATS2 and YAP. Anti-Actin was used to control for loading. (D) Luciferase reporter assays showing
the effects of DUB3 siRNAs on YAP/TAZ activity. HEK293T cells were transfected to express the luciferase
reporters together with a control or DUB3 siRNA in the presence of a mixture of siRNAs targeting AMOT,
AMOTL1 and AMOTL2, a mixture of siRNAs targeting LATS1 and LATS2 or a scrambled siRNA control. Data
represent the average of three independent transfection experiments ± SD. P values were determined using
Student’s T-test (2-tailed, unequal variance).
doi:10.1371/journal.pone.0169587.g003
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AMOT and LATS1/2 are required for the effect of DUB3 on YAP
AMOT proteins have been proposed to play a scaffolding role, mediating the interaction
between ITCH and YAP, to promote YAP ubiquitylation [35]. AMOT proteins also inhibit
YAP/TAZ activity through direct physical association and by promoting LATS-mediated
phosphorylation of YAP [16,17]. In light of this, we asked if AMOT and the related AMOTL1
and AMOTL2 proteins are required to mediate the effect of DUB3 on LATS kinase and YAP
levels. In cells depleted of AMOT, AMOTL1 and AMOTL2, we observed no stabilization of
LATS1 or LATS2 proteins following DUB3 overexpression (Fig 3A). The decrease in YAP
protein levels caused by DUB3 expression was also lost in the AMOT-depleted cells (Fig 3A).
Likewise, the effects of depleting DUB3 on LATS1/2 and YAP protein levels were lost in cells
depleted of the AMOT family proteins (Fig 3B). Thus AMOT proteins are required for DUB3
to act on LATS2 and YAP protein levels. Consistent with this, the effects of DUB3 siRNA on
YAP reporter activity were significantly blunted by depletion of AMOT proteins (Fig 3D).
Next we asked whether depleting the LATS1/2 kinases would block the effects of DUB3 on
YAP levels. DUB3 depletion led to an increase in YAP levels (Fig 3C). Depletion of LATS1/2
kinases led to an increase in the basal level of YAP protein, but there was no further effect of
DUB3 on YAP (Fig 3C). However, LATS1/2 depletion did not prevent the effects of DUB3 on
ITCH (Fig 3C). We also noted that depletion of LATS1/2 resulted in loss of AMOT protein
(Fig 3C). LATS-mediated phosphorylation has previously been reported to stabilize AMOT
[36], so loss of AMOT is an expected consequence of LATS1/2 depletion. This experiment pro-
vides evidence that LATS1/2 proteins are required to mediate the effects of DUB3 on regula-
tion of YAP activity. This is likely to occur through both through regulating AMOT turnover
as well as through their direct phosphorylation of YAP. Consistent with this, the effects of
DUB3 on YAP reporter activity were significantly blunted by depletion of LATS1/2 proteins
(Fig 3D).
Our findings provide evidence that the DUB3 deubiquitylating enzyme acts at several levels
to regulate the activity of the Hippo tumor suppressor pathway (Illustrated in Fig 4A). We
have identified the E3 Ligase ITCH, LATS1/2 and AMOT as targets for the deubiquitylating
activity of DUB3. Each of these proteins serves as regulators of YAP activity.
AMOT proteins have been proposed to provide a platform linking the E3 ligase ITCH and
YAP [35]. We confirmed this relationship using the YAP luciferase reporter assay, comparing
the effects of ITCH expression in cells depleted of AMOT, AMOTL1 and AMOTL2 with con-
trol cells. ITCH expression increased YAP/TAZ activity in control cells, but had no effect in
cells lacking the AMOT proteins (Fig 4B; note that the basal level of YAP activity was higher
in AMOT-depleted cells). Similarly, removing LATS kinase activity prevented ITCH from
increasing YAP activity (Fig 4B). Note that AMOT protein was lost in cells depleted of LATS
kinases, so we hypothesize that the effect of either siRNA treatment would be to eliminate the
scaffold linking ITCH and YAP (Fig 4A). LATS kinases also phosphorylate YAP and TAZ and
target them for destruction by the βTrCP/SCF ubiquitin ligase system [10,11]. By helping to
stabilize AMOT, the LATS kinases also promote interaction of ITCH with YAP/TAZ, provid-
ing another means to promote YAP/TAZ turnover.
DUB3 limits YAP activity by stabilizing the ubiquitin E3 ligase ITCH concurrently with
stabilization of LATS kinases and AMOT proteins. The effects of DUB3 on YAP depend on
the presence of AMOT proteins, suggesting that this activity occurs in the context of a pro-
tein complex containing the E3 ligase and its substrates. Whether DUB3 is a stable member
of this complex containing ITCH, AMOT and LATS kinases is uncertain. DUB3 binds effec-
tively to ITCH, but its association with LATS or AMOT appeared to be less stable in co-IP
experiments.
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We favor a model in which inhibition of Hippo signaling by DUB3 reflects contributions of
DUB3 in stabilizing the AMOT proteins and LATS1/2. Although DUB3 also stabilizes the E3
ligase ITCH, interaction of DUB3 with LATS1/2 and AMOT in this complex is hypothesized
to offset the effects of increased ITCH activity toward these substrates. On the other hand, the
increased expression of ITCH may facilitate interaction with YAP. Thus DUB3 activity can
promote the stability of LATS1/2 and AMOT, which act to reduce YAP activity and increase
YAP turnover, while also increasing expression of ITCH, which can promote YAP turnover.
Depletion of ITCH from this complex reduces the effects of DUB3 on YAP, and this effect was
stronger when NEDD4, another E3 ligase was also removed (Fig 4C). This suggests that multi-
ple E3 ligases can serve in this complex to regulate YAP. Similarly, any of the three AMOT pro-
teins appears to support the activity of DUB3 on YAP activity.
Evidence for links between DUB3 family members and cancer remain equivocal. One study
has provided evidence that a DUB3 family might serve as an oncogene by stabilizing CDC25A
and promoting cell cycle progression in breast cancer [37]. In another study the DUB3 para-
log, USP17 was reported to limit cell cycle progression by inhibiting RAS activity [38]. Our
findings suggest that members of the DUB3 family have the potential to act as tumor suppres-
sors by limiting YAP activity. However, given that there are multiple genes encoding DUB3
Fig 4. DUB3 mediates ITCH, LATS1/2 and AMOT proteins to regulate Hippo activity. (A) A schematic
view of DUB3-mediated regulation of Hippo signaling. DUB3 de-ubiquitylates ITCH, LATS1/2 and AMOT to
promote their stability. In the presence of stabilized AMOT, ITCH promotes YAP degradation. (B) Luciferase
reporter assays showing the effects of ITCH overexpression on YAP/TAZ activity. HEK293T cells were
transfected to express the luciferase reporters together with a control or ITCH expression vector in the
presence of a mixture of siRNAs targeting AMOT, AMOTL1 and AMOTL2, a mixture siRNAs targeting LATS1
and LATS2 or a scrambled siRNA control. Data represent the average of three independent transfection
experiments ± SD. (C) Luciferase reporter assays showing the effects of DUB3 siRNAs on YAP/TAZ activity.
HEK293T cells were transfected to express the luciferase reporters together with a control or DUB3 siRNA in
the presence of ITCH siRNA, a mixture of siRNAs targeting ITCH and NEDD4 or a scrambled siRNA control.
Data represent the average of three independent transfection experiments ± SD.
doi:10.1371/journal.pone.0169587.g004
Regulation of the Hippo Pathway by Dub3 Deubiquitylases
PLOS ONE | DOI:10.1371/journal.pone.0169587 January 6, 2017 10 / 15
family members, at distinct chromosomal locations, it is unlikely that this activity will be
uncovered by loss of function mutations in human cancer.
Supporting Information
S1 Fig. Summary of DUB3 family members. The NCBI RefSeq Gene collection comprises 30
USP17L (USP17L1 through USP17L30) gene entries: 25 are annotated as protein coding genes
(each with an individual mRNA and protein RefSeq), while four are annotated as pseudogenes
(USP17L6P, -9P, -14P, -16P), and one (USP17L23) is annotated as protein coding gene, but
not linked to either a RefSeq mRNA or protein sequence. (http://www.ncbi.nlm.nih.gov/
books/NBK21091). The table summarizes the number of mismatches between the individual
siRNAs and shRNAs with the family members.
(PDF)
S2 Fig. Effect of shRNAs and siRNAs on DUB3 mRNA expression. Controls for the efficacy
of shRNAs and siRNAs on DUB3 mRNA expression. (A) HEK293T cells were transfected with
a control vector or with independent shRNAs targeting DUB3. (B) HEK293T cells were trans-
fected with a control siRNA (scrambled sequence) or independent siRNAs targeting DUB3.
Expression of DUB3 mRNA was measured by quantitative real-time RT-PCR (qPCR) using
two independent pairs of primers. Primer pair #1 was used subsequently for measuring DUB3
expression. GAPDH mRNA was used for normalization. Data represent the average of 3 inde-
pendent experiments ± SD.  indicates p<0.05 (Student’s T-test, 2-tailed unequal variance)
comparing the test and control samples.
(PDF)
S3 Fig. controls for the effects of DUB3 depletion. HEK293T cells were transfected with a
vector expressing DUB3 or the catalytically-inactive C89S mutant form or with an empty vec-
tor as a control. mRNA expression of YAP, TAZ, ITCH, AMOT, AMOT L1, AMOT L2,
LATS1, LATS2 and DUB3 was measured by qPCR. GAPDH mRNA was used as a normaliza-
tion standard and TBP was used as an independent control. Data represent the average of 3
independent experiments ± SD.
(PDF)
S4 Fig. DUB3 regulates the stability of Hippo proteins in BJ cells. (A) BJ fibroblast cells
expressing hTert and H-RasG12V and depleted of p53 and p16 (BJp53kd/p16kd/HRas) were virally
transduced and selected to express DUB3, its inactive C89S mutant form or an empty control
vector. Cells were plated for 36h before being harvested for immunoblotting. Blots were probed
with antibodies against Flag, DUB3, ITCH, phospho-LATS1/2 (T1079/1041), LATS1, AMOT
L1, phospho-YAP S127, YAP and actin. (B) BJp53kd/p16kd/HRas cells were virally transduced and
selected to stably express either a control vector or independent shRNAs against DUB3 and pro-
cessed as in (A). (C) BJp53kd/p16kd/HRas cells were transfected to express the luciferase reporters
together with siRNAs to deplete DUB3 or with a control scrambled siRNA. Data represent the
average of three independent transfection experiments ± SD.
(PDF)
S5 Fig. YAP localization in BJ cells depleted of DUB3. (A) BJp53kd/p16kd/HRas cells were seeded
for 24h before being transfected with DUB3-specific siRNAs or scrambled controls. Transfected
cells were fixed after 36h and stained with YAP antibody (Santa Cruz, sc-101199). qPCR was
used to confirm the depletion of DUB3. (B) Representative images of BJ cells stained with anti-
YAP treated as described in panel A. YAP localization was scored as: less YAP in the nucleus
compared to the cytoplasm (e.g. white arrows); equal in cytoplasm and nucleus (e.g. blue arrows);
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and YAP higher in the nucleus (e.g. red arrows). (C) DUB3 depletion caused a significant shift
towards nuclear YAP (p<0,0001; Chi-square test).
(PDF)
S6 Fig. Effect of DUB3 expression on NEDD4 E3 ligase family members. HEK293T cells
were transfected with a vector expressing DUB3 or the inactive C89S mutant form or with an
empty vector as a control. mRNA expression of NEDD4, ITCH and SMURF1 was measured
by qPCR. GAPDH mRNA was used for normalization and TBP was used as an independent
control. Data represent the average of 3 independent experiments ± SD.
(PDF)
S7 Fig. Interaction between endogenous ITCH and DUB3. Immunoprecipitation assays.
HEK293T cells were treated with 5μM MG132 to block proteasome function 24h before
cells were harvested for IP by lysing in PLC buffer, or a modified RIPA buffer containing
10% glycerol. Lysates were immunoprecipitated with anti-ITCH or anti-DUB3 antibodies
or isotype-matched control antibodies. Blots were probed with anti-ITCH, anti-DUB3 anti-
bodies. Endogenous ITCH was recovered in the DUB3 IP, but DUB3 was not recovered in
the ITCH IP.
(PDF)
S8 Fig. DUB3 depletion increases ubiquitylation of ITCH. HEK293T cells were transfected
to express Myc-tagged ITCH along with ubiquitin and siRNA targeting DUB3 or a scrambled
control siRNA. Transfected cells were treated with 5μM of MG132 and 5μM of Lactacystin
overnight before being subjected to immunoprecipitation with anti-Myc. Blots were probed
with antibodies against DUB3, actin, and the Myc epitope to detect Myc-tagged ITCH and
with antibodies specific to ubiquitin linked at lysine residues K48 and K63.
(PDF)
S9 Fig. DUB3 affects ubiquitylation of AMOT protein. (A) HEK293T cells were trans-
fected to express HA-tagged AMOT along with ubiquitin and DUB3 siRNA or a scram-
bled siRNA. Transfected cells were treated with 5μM of MG132 and 5μM of Lactacystin
overnight before being subjected to immunoprecipitation with anti-HA. Blots were pro-
bed with antibodies against HA, DUB3, actin and specific lysine residues K48 and K63 of
ubiquitin. (B) HEK293T cells were transfected to express HA-tagged AMOT together with
ubiquitin and Flag-DUB3 or Flag-DUB3 C89S. Blots were probed with antibodies against
Myc, HA, DUB3, actin.
(PDF)
S10 Fig. DUB3 interacts with LATS2 protein and suppresses its ubiquitylation. (A)
HEK293T cells were transfected to express Flag-DUB3, its inactive mutant C89S or a control
vector. Transfected cells were treated with 5μM of MG132 overnight before being subjected to
immunoprecipitation with anti-Flag. Blots were probed with antibodies against Flag, LATS2,
HA and actin. (B) HEK293T cells were transfected to express HA-LATS2 and myc-ubiquitin
along with Flag-DUB3, its inactive mutant C89S or a control vector. Cells were treated with
5μM of MG132 overnight before being subjected to immunoprecipitation with anti-HA. Blots
were probed with antibodies against Myc, LATS2, HA, DUB3 and actin.
(PDF)
S1 Table. Sequences of shRNA targets, siRNAs and qPCR primers.
(PDF)
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